Altimmune Past Earnings Performance

Past criteria checks 0/6

Altimmune's earnings have been declining at an average annual rate of -20.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 48.8% per year.

Key information

-20.1%

Earnings growth rate

8.4%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate-48.8%
Return on equity-77.6%
Net Margin-199,076.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Altimmune makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0A4C Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-104200
30 Jun 240-101200
31 Mar 240-93190
31 Dec 230-88180
30 Sep 230-78180
30 Jun 230-81180
31 Mar 230-85170
31 Dec 220-85170
30 Sep 223-87170
30 Jun 223-97170
31 Mar 224-102160
31 Dec 214-97150
30 Sep 213-84160
30 Jun 216-68160
31 Mar 217-60150
31 Dec 208-49130
30 Sep 206-43110
30 Jun 204-3690
31 Mar 205-2290
31 Dec 196-2190
30 Sep 198-4290
30 Jun 1910-3490
31 Mar 1911-4090
31 Dec 1810-42100
30 Sep 1811-2990
30 Jun 1813-58100
31 Mar 1813-52100
31 Dec 1711-5180
30 Sep 179-4380
30 Jun 175-1680
31 Mar 173-1470
31 Dec 163-1160
30 Sep 163-1050
31 Dec 155-750
31 Dec 146-110

Quality Earnings: 0A4C is currently unprofitable.

Growing Profit Margin: 0A4C is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0A4C is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare 0A4C's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0A4C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 0A4C has a negative Return on Equity (-77.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies